VKH
GNCA

Virtu KCG Holdings’s Genocea Biosciences, Inc. GNCA Stock Holding History

Virtu KCG Holdings’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-6,839
Closed -$225K – 4040
2016
Q4 		$225K Buy
6,839
+5,019
+276% +$165K 0.01% 2450
2016
Q3 		$75K Sell
1,820
-1,098
-38% -$43.1K ﹤0.01% 2714
2016
Q2 		$96K Buy
+2,918
New +$107K ﹤0.01% 2550

Other funds holding GNCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return

Virtu KCG Holdings's GNCA Position: Q1 2017 in Review

Virtu KCG Holdings sold out of Genocea Biosciences, Inc. (GNCA) in Q1 2017, closing a stake of 6,839 shares — an estimated $225K sold.

Virtu KCG Holdings first reported a position in GNCA in Q2 2016 and held it in 3 quarters. The position peaked at $225K in Q4 2016. 49 funds tracked by Wall St. Rank hold GNCA as of Q1 2017.

  • Virtu KCG Holdings reported no remaining Genocea Biosciences, Inc. position as of Q1 2017 after selling out during the quarter.
  • Virtu KCG Holdings sold 6,839 Genocea Biosciences, Inc. shares in Q1 2017, an estimated $225K.
  • Virtu KCG Holdings first reported a position in Genocea Biosciences, Inc. in Q2 2016 and held it in 3 quarters.
  • Virtu KCG Holdings's Genocea Biosciences, Inc. position peaked at $225K in Q4 2016.
  • 49 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q1 2017.

Based on Virtu KCG Holdings's 13F filing for Q1 2017, filed 12 May 2017.